HKU Scholars Hub: Browsing DSpace

Browsing by Author Massetto, B

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 4 of 4

	Title	Author(s)	Issue Date
	Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in Asian and non-Asian subjects with chronic hepatitis B (CHB) Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Yuen, RMF Agarwal, K Gane, E Jucov, A Schwabe, C Le, K Massetto, B Westland, C Zhang, QL Blatt, L Lin, T-I Chanda, S Mcclure, M Fry, J	2022
	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Chan, HL Fung, S Seto, WKW Chuang, WL Chen, CY Kim, HJ Hui, AJ Janssen, H Chowdhury, A Tsang, TY Rajiv, M Gane, E Flaherty, J Massetto, B Gaggar, A Kitrinos, KM Lin, L Subramanian, GM McHutchison, J Lim, YS Acharya, SK Agarwal, K	2016
	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Buti, M Gane, E Seto, WKW Chan, HL Chuang, WL Stepanova, T Hui, AJ Lim, YS Mehta, R Janssen, H Acharya, SK Flaherty, J Massetto, B Cathcart, AL Kim, K Gaggar, A Subramanian, GM McHutchison, J Pan, C Brunetto, M Izumi, N Marcellin, P	2016
	The Capsid Assembly Modulator ALG-000184 dosed for 28 days was well tolerated and rapidly reduced viral markers in subjects with chronic hepatitis B, including HBsAg in a subset of HBeAg positive subjects with elevated baseline ALT Proceeding/Conference:Hepatology International	Gane, E Yuen, MF Agarwal, K Juov, A Hou, J Niu, J Massetto, B Le, K Lin, TI McClure, M	31-Mar-2023

Showing results 1 to 4 of 4